Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Rates
    • Journal Claims
    • Institutional and Non-member
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
    • Corporate & Special Sales
  • About
    • About Us
    • Editorial Board
    • Editorial Contact
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Rates
    • Journal Claims
    • Institutional and Non-member
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
    • Corporate & Special Sales
  • About
    • About Us
    • Editorial Board
    • Editorial Contact
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow SNMMI on Twitter
  • Visit SNMMI on Facebook

prostate-specific membrane antigen

  • You have access
    PSMA-Targeted Therapeutics: A Tale About Law and Economics
    Johannes Notni
    Journal of Nuclear Medicine March 31, 2021, jnumed.121.262308; DOI: https://doi.org/10.2967/jnumed.121.262308
  • <sup>177</sup>Lu-Labeled Albumin-Binder–Conjugated PSMA-Targeting Agents with Extremely High Tumor Uptake and Enhanced Tumor-to-Kidney Absorbed Dose Ratio
    You have access
    177Lu-Labeled Albumin-Binder–Conjugated PSMA-Targeting Agents with Extremely High Tumor Uptake and Enhanced Tumor-to-Kidney Absorbed Dose Ratio
    Hsiou-Ting Kuo, Kuo-Shyan Lin, Zhengxing Zhang, Carlos F. Uribe, Helen Merkens, Chengcheng Zhang and François Bénard
    Journal of Nuclear Medicine April 1, 2021, 62 (4) 521-527; DOI: https://doi.org/10.2967/jnumed.120.250738
  • You have access
    Head to head comparison of 68Ga-NGUL and 68Ga-PSMA-11 in patients with metastatic prostate cancer: a prospective study
    Minseok Suh, Hyung-Jun Im, Hyun Gee Ryoo, Keon Wook Kang, Jae Min Jeong, Sneha Prakash, Sanjana S Ballal, Madhav P Yadav, Chandrasekhar Bal, Chang Wook Jeong, Cheol Kwak and Gi Jeong Cheon
    Journal of Nuclear Medicine March 26, 2021, jnumed.120.258434; DOI: https://doi.org/10.2967/jnumed.120.258434
  • Open Access
    Head-to-head comparison of 68Ga-prostate-specific membrane antigen PET/CT and ferumoxtran-10 enhanced MRI for the diagnosis of lymph node metastases in prostate cancer patients
    Melline GM Schilham, Patrik Zamecnik, Bastiaan M Privé, Bas Israël, Mark Rijpkema, Tom Scheenen, Jelle O Barentsz, James Nagarajah and Martin Gotthardt
    Journal of Nuclear Medicine January 30, 2021, jnumed.120.258541; DOI: https://doi.org/10.2967/jnumed.120.258541
  • You have access
    The Effects of Monosodium Glutamate on PSMA Radiotracer Uptake in Men with Recurrent Prostate Cancer: A Prospective, Randomized, Double-Blind, Placebo-Controlled Intraindividual Imaging Study
    Sara Harsini, Heather Saprunoff, Tina Alden, Behnoud Mohammadi, Don Wilson and François Bénard
    Journal of Nuclear Medicine January 1, 2021, 62 (1) 81-87; DOI: https://doi.org/10.2967/jnumed.120.246983
  • You have access
    Positive predictive value and correct detection rate of 18F-rhPSMA-7 PET in biochemically recurrent prostate cancer validated by composite reference standard
    Maythinee Chantadisai, Gabriel Buschner, Markus Krönke, Isabel Rauscher, Thomas Langbein, Stephan G. Nekolla, Kilian Schiller, Matthias M. Heck, Tobias Maurer, Alexander Wurzer, Hans-Juergen Wester, Calogero D'Alessandria, Wolfgang Weber and Matthias Eiber
    Journal of Nuclear Medicine November 27, 2020, jnumed.120.255661; DOI: https://doi.org/10.2967/jnumed.120.255661
  • You have access
    Neuroendocrine Differentiation and Response to PSMA-Targeted Radioligand Therapy in Advanced Metastatic Castration-Resistant Prostate Cancer: A Single-Center Retrospective Study
    Thorsten Derlin, Rudolf A. Werner, Marcel Lafos, Christoph Henkenberens, Christoph A.J. von Klot, Jan M. Sommerlath Sohns, Tobias L. Ross and Frank M. Bengel
    Journal of Nuclear Medicine November 1, 2020, 61 (11) 1602-1606; DOI: https://doi.org/10.2967/jnumed.120.241588
  • You have access
    Early Prostate-Specific Antigen Changes and Clinical Outcome After 177Lu-PSMA Radionuclide Treatment in Patients with Metastatic Castration-Resistant Prostate Cancer
    Andrei Gafita, Matthias M. Heck, Isabel Rauscher, Robert Tauber, Lisena Cala, Charlott Franz, Calogero D’Alessandria, Margitta Retz, Wolfgang A. Weber and Matthias Eiber
    Journal of Nuclear Medicine October 1, 2020, 61 (10) 1476-1483; DOI: https://doi.org/10.2967/jnumed.119.240242
  • You have access
    Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of 177Lu-PSMA-617 Theranostics in Metastatic Castration-Resistant Prostate Cancer
    John Violet, Shahneen Sandhu, Amir Iravani, Justin Ferdinandus, Sue-Ping Thang, Grace Kong, Aravind Ravi Kumar, Tim Akhurst, David Pattison, Alexis Beaulieu, Jennifer Mooi, Ben Tran, Christina Guo, Victor Kalff, Declan G Murphy, Price Jackson, Peter Eu, Mark Scalzo, Scott Williams, Rodney J. Hicks and Michael S. Hofman
    Journal of Nuclear Medicine June 1, 2020, 61 (6) 857-865; DOI: https://doi.org/10.2967/jnumed.119.236414
  • You have access
    3-Year Freedom from Progression After 68Ga-PSMA PET/CT–Triaged Management in Men with Biochemical Recurrence After Radical Prostatectomy: Results of a Prospective Multicenter Trial
    Louise Emmett, Reuben Tang, Rohan Nandurkar, George Hruby, Paul Roach, Jo Anne Watts, Thomas Cusick, Andrew Kneebone, Bao Ho, Lyn Chan, Pim J. van Leeuwen, Matthijs J. Scheltema, Andrew Nguyen, Charlotte Yin, Andrew Scott, Colin Tang, Michael McCarthy, Karen Fullard, Matthew Roberts, Roslyn Francis and Phillip Stricker
    Journal of Nuclear Medicine June 1, 2020, 61 (6) 866-872; DOI: https://doi.org/10.2967/jnumed.119.235028

Pages

  • Next
  • 1
  • 2
  • 3
  • 4
SNMMI

© 2021 Journal of Nuclear Medicine

Powered by HighWire